Transplantation tolerance, a state of long-lasting immune unresponsiveness to donor antigens after cessation of therapy, is an attractive approach for life-long graft acceptance without global immunosuppression. Long-term follow up of tolerant patients has revealed that tolerance can be lost in some individuals after years of graft stability, sometimes after infections, raising 2 possibilities: that tolerance at induction was equally robust but some patients were exposed to more inflammatory events that eroded the state of tolerance, or that tolerance at induction was metastable in some patients and robust in others. The first cycle of our Program Project addressed the first possibility using a mouse model of transplantation tolerance that is robust and resistant to most inflammatory challenges with the exception of Listeria monocytogenes (Lm). Importantly, we tracked alloreactive T cells by analyzing small numbers of congenic TCR-Tg alloreactive T cells seeded before transplantation, or using fluorescent pMHC Class I and Class II multimers to identify endogenous populations of T cells reactive to model donor antigens. By comparing alloreactive T cells before (Project 1) and after (Project 2) Lm infection of tolerant mice, our Program discovered that i) robust transplantation tolerance is maintained by multiple redundant mechanisms of T cell tolerance, including constraining alloreactive T cell numbers, increasing the ratio of regulatory to conventional T cells, inhibiting conventional T cells intrinsically and restraining alloreactive T cell populations to clones with low avidity for alloantigen; ii) robust tolerance is resilient because it spontaneously returned in animals that experienced Lm-dependent graft rejection; iii) tolerance after infection is eroded and dependent on single mechanisms of T cell tolerance such that blockade of PD-L1 or depletion of Tregs was sufficient to precipitate graft rejection in tolerant hosts post-infection but not in uninfected hosts. Globally, our Program has demonstrated that transplantation tolerance is not an all-or-none state, but rather can exist at different levels of robustness. These observations highlight the need to precisely define and monitor the mechanisms underlying graft acceptance in each tolerant recipient and to devise strategies to improve tolerance when it becomes eroded. For this Competitive Renewal, we will address the second possibility, that not all patients achieve robust tolerance at induction. Globally, we hypothesize that the mechanisms restraining alloreactive T cell subsets can distinguish robust tolerance established in naive hosts from eroded tolerance after infection, and from metastable or failed tolerance in sensitized hosts. Project 1 will focus on 2 novel features of alloreactive T cells that we recently discovered as characteristic of robust transplantation tolerance in nave hosts, namely, cell intrinsic hyporesponsiveness and the constraint of alloreactive T cells to low avidity clones Project 2 will study how allosensitization, a major barrier to the induction of transplantation tolerance, affects the induction of the individual mechanisms of T cell tolerance that characterize robust tolerance.

Public Health Relevance

PROGRAM NARRATIVE Transplantation tolerance can be achieved in a small subset of non-allosensitized patients, but graft loss can still occur after years of stability, sometimes after infections. Using a mouse model of donor-specific life- long tolerance, our results show that infections can erode robust transplantation tolerance such that mechanisms of peripheral T cell tolerance maintaining graft survival become non-redundant. Project 1 will focus on 2 novel mechanisms of T cell tolerance that are features of robust tolerance and determine how they are affected by infection, while Project 2 will study how allosensitization prior to transplantation, with skin transplantation or allogeneic pregnancy, affects the individual mechanisms of T cell tolerance.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Kehn, Patricia J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Chicago
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Alegre, Maria-Luisa (2018) What's new in transplantation tolerance? Curr Opin Organ Transplant 23:63-65
Miller, Michelle L; McIntosh, Christine M; Williams, Jason B et al. (2018) Distinct Graft-Specific TCR Avidity Profiles during Acute Rejection and Tolerance. Cell Rep 24:2112-2126
Chong, Anita S; Ansari, M Javeed (2018) Heterogeneity of memory B cells. Am J Transplant 18:779-784
Young, James S; Khiew, Stella H-W; Yang, Jinghui et al. (2017) Successful Treatment of T Cell-Mediated Acute Rejection with Delayed CTLA4-Ig in Mice. Front Immunol 8:1169
Khiew, Stella H; Yang, Jinghui; Young, James S et al. (2017) CTLA4-Ig in combination with FTY720 promotes allograft survival in sensitized recipients. JCI Insight 2:
Young, James S; McIntosh, Christine; Alegre, Maria-Luisa et al. (2017) Evolving Approaches in the Identification of Allograft-Reactive T and B Cells in Mice and Humans. Transplantation 101:2671-2681
Young, J S; Daniels, M D; Miller, M L et al. (2017) Erosion of Transplantation Tolerance After Infection. Am J Transplant 17:81-90
Miller, Michelle L; Alegre, Maria-Luisa; Chong, Anita S (2017) Transplantation tolerance after allograft rejection. Curr Opin Organ Transplant 22:64-70
Chong, A S; Khiew, S H (2017) Transplantation tolerance: don't forget about the B cells. Clin Exp Immunol 189:171-180
Chong, Anita S (2017) Alone Again, Naturally: B Cells Encountering Antigen Without T cells. Transplantation 101:1956-1958

Showing the most recent 10 out of 33 publications